EXPERTS IN DRUG DISCOVERY AND DEVELOPMENT

ENDECE is focused on developing proprietary novel drugs that impact lung inflammation, neuroinflammation and neurodegeneration in chronic, debilitating, and life threatening diseases for which treatment options are limited or non-existent. Our library of proprietary compounds is designed to activate multiple genes within specific biological pathways to stop progression, repair damage, and restore function for people with diseases such as Multiple Sclerosis (MS), Acute Respiratory Distress Syndrome (ARDS), Alzheimer’s Disease (AD), Niemann-Pick disease type C (NPC1), Neuromyelitis Optica Spectrum Disorder (NMOSD), and Osmotic Demyelination Syndrome (ODS).

REMYELINATION

NDC-1308 directly up-regulates key genes within Oligodendrocyte Progenitor Cells (OPCs) of the Central Nervous System (CNS), inducing OPC differentiation.

NDC-1308: ANTI-INFLAMMATORY

Increases the expression of lipoprotein lipase (LPL) and apolipoprotein C2 (ApoC2) genes within macrophages causing polarization to the M2, anti-inflammatory, pro-repair state.

ENDECE PIPELINE

Niemann-Pick disease type C NPC1
Multiple Sclerosis
Alzheimer's Disease
Niemann-Pick disease type C NPC1
Neuromyelitis Optica Spectrum Disorder NMOSD
Osmotic Demyelination Syndrome
ENDECE COVID-19 SARS-CoV-2

Multiple Sclerosis

  • Neuroinflamation / Neurodegeneration
  • Administration:
  • Intranasal delivery via nebulizor through the olfactory epithelium to the CNS

  • discovery | preclinical | IND enabeling
  • Multiple Sclerosis (MS) is an unpredictable, debilitating disease of the Central Nervous System (CNS). Nearly ONE MILLION people are living with MS in the United States, more than twice the original estimates.

Alzheimer’s Disease

  • Neuroinflamation / Neurodegeneration
  • Administration:
  • Intranasal delivery via nebulizor through the olfactory epithelium to the CNS

  • discovery
  • Alzheimer’s Disease has been an irreversible and progressive brain disorder that reduces memory, cognition, and one’s ability to execute the simplest tasks. Symptoms usually appear when a patient is in mid 60’s.

Niemann-Pick disease type C (NPC1)

  • Neuroinflamation / Neurodegeneration
  • Administration:
  • Intranasal delivery via nebulizor through the olfactory epithelium to the CNS

*RARE DISEASE

  • discovery | preclinical
  • Niemann-Pick disease type C (NPC1) is a rare genetic disorder in which gene mutations are passed from parents to children in a pattern called autosomal recessive inheritance, leading to progressive and lethal neurodegeneration.

Neuromyelitis Optica Spectrum Disorder (NMOSD)

  • Neuroinflamation / Neurodegeneration
  • Administration:
  • Intranasal delivery via nebulizor through the olfactory epithelium to the CNS

*RARE DISEASE

  • discovery | preclinical
  • Neuromyelitis Optica Spectrum Disorder (NMOSD) is an autoimmune disease of the Central Nervous System (CNS) in which the immune system attacks the optic nerve and spinal cord. NMOSD is identified by the presence of antibodies to aquaporin-4 (AQP4), which distinguishes it from MS.

Osmotic Demyelination Syndrome (ODS)

  • Neuroinflamation / Neurodegeneration
  • Administration:
  • Intranasal delivery via nebulizor through the olfactory epithelium to the CNS

  • discovery | preclinical
  • Osmotic Demyelination Syndrome (ODS), also called Central Pontine Myelinolysis (CPM) and Extra Pontine Myelinolysis (EPM), is a demyelination within the pons region of the Central Nervous System (CNS) that interrupts the flow of information between the brain and body.

ARDS

NDC-1308 reduces respiratory distress

  • Lung Inflammation

Administration
 

  • Inhalation / nebulizor directly to the lungs
  • discovery | preclinical | IND enabeling
  • In cases of pulmonary infections, M1 macrophages become the first line of defense and most often eliminate the infection. However, the M1 macrophages can lead to hyper-inflammation. Prolonged inflammation within the lungs causes respiratory distress and respiratory failure, leading to Acute Respiratory Distress Syndrome (ARDS), as well as Cytokine Storm. ENDECE developed NDC-1308, a small molecule, which upregulates the gene responsible for lipoprotein lipase (LPL) production. By directly increasing LPL levels within lung macrophages, NDC-1308 polarizes them from the M1 (pro-inflammatory, anti-repair) state to the M2 (anti-inflammatory, pro-repair) state thereby reducing the risk of acute respiratory failure and the need for mechanical ventilators.